28 02, 2020

One Perspective on the BLU-285 Trial (avapritinib/Ayvakit)

By |2020-03-09T10:18:42-04:00February 28th, 2020|D842V, News, Newsletter|

LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.

7 02, 2020

NCI Mentions LRG as Component in Development of Ayvakit

By |2020-02-07T14:23:48-05:00February 7th, 2020|D842V, Drug Treatment, News, Patient Registry|

In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.

30 06, 2021

Spotlight on LRG Global Representatives – Nandini Dabbir, India

By |2021-06-30T10:50:44-04:00June 30th, 2021|Global, News, Newsletter|

The newest GISTer to join the ranks of LRG Global Representatives is Nandini Dabbir of Hyderabad, India. She is a the Friends of Max City Chapter Leader & GIST Advocate working with the LRG to support GIST patients on their journey.

11 06, 2021

It’s Time: The Life Raft Group Biomarker Testing Campaign – Advocate for this Lifesaving Tool

By |2021-09-27T14:46:46-04:00June 11th, 2021|Mutational Testing, News|

Uncovering the driving force behind each individual’s tumors is not just important, it is critical. In this post, we feature sarcoma experts discussing biomarker testing.

14 05, 2021

It’s Time: The Life Raft Group Biomarker Testing Campaign – Empower Patients

By |2021-09-27T14:52:52-04:00May 14th, 2021|Mutational Testing, News|

As part of our 'It's Time' campaign, we are sharing Blueprint Medicines's tools for talking to your doctor about biomarker/mutational testing.

25 02, 2021

Heroes of Rare Disease: The 2021 Rare Impact Awards

By |2021-06-28T14:47:31-04:00February 25th, 2021|News, Research|

June 28th Awards Ceremony registration:   https://livingrare.org/rare-impact-awards/ Dr. Jason Sicklick, Blueprint Medicines Among Honorees Released 2/23/21 by NORD The National Organization for Rare Disorders (NORD®) announced this year’s Rare Impact Award honorees. These outstanding [...]

30 06, 2020

Blueprint Medicines Announces Publication in The Lancet Oncology

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

15 05, 2020

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top